Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium-glucose cotransporters are integral membrane proteins that mediate the active transport of glucose across cell membranes by coupling glucose uptake to the inward movement of sodium ions. SGLT1 is mainly expressed in the small intestine where it is essential for absorbing dietary glucose and galactose, and accounts for a small fraction of renal glucose reabsorption. SGLT2 is predominantly found in the renal proximal convoluted tubule and is responsible for reabsorbing the majority of glucose filtered by the kidneys. Inhibition of SGLT2 increases urinary glucose excretion and is the basis for several antidiabetic drugs. Dysfunction or genetic defects in SGLT1 or SGLT2 can lead to specific malabsorption syndromes or glycosuria. The SGLT family is distinct from the facilitative glucose transporter (GLUT) family, which mediates passive glucose movement[1][2][3].
Inhibition of renal glucose reabsorption by blocking SGLT2 (and SGLT1, by dual inhibitors), lowering blood glucose, promotion of glucosuria
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-glucose cotransporter 1 and Sodium-glucose cotransporter 2 (SGLT1 and SGLT2).